Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Niraparib + Dostarlimab for Pancreatic Cancer
Recruiting1 awardPhase 2
Rochester, Minnesota
This trial studies niraparib and dostarlimab as a treatment for pancreatic cancer that has spread to other places in the body and has mutations in the BRCA1/2 or PALB2 gene.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service